Reported Saturday, Delcath Systems Posts $20.5M Q3 Revenue, $0.8M Net Income And 87% Gross Margin; Sees 2025 Revenue Outlook Of $83M–$85M With 150% Treatment Volume Growth Forecast
Benzinga Newsdesk 1 year ago
News
Preliminary Third Quarter Financial Results (unaudited)Total CHEMOSAT and HEPZATO KIT revenue of approximately $20.5 millionHEPZATO KIT revenue of $19.2 millionCHEMOSAT revenue of $1.3 millionGross margins expected to be
Preliminary Third Quarter Financial Results (unaudited)
- Total CHEMOSAT and HEPZATO KIT revenue of approximately $20.5 million
- HEPZATO KIT revenue of $19.2 million
- CHEMOSAT revenue of $1.3 million
- Gross margins expected to be 87%
Net income of $0.8 million
- Positive adjusted EBITDA of $5.3 million
Positive operating cashflow of approximately $4.8 million
As of September 30, 2025, the Company had approximately $88.9 million of cash, cash equivalents and short-term investments and no debt.
2025 Full Year Financial Guidance
- Total CHEMOSAT and HEPZATO KIT revenue of $83 million to $85 million, reflecting an approximate 150% increase in treatment volume over 2024
- Quarterly gross margins between 85% to 87%
- Positive adjusted EBITDA and operating cashflow in each quarter of 2025